Skip to content

Evaluating drug’s performance, finding tomorrows blockbusters

Drug discovery

We can adapt the ANCHOR™ system to any kind of DNA, whether it is viral, animal or plant cell-based

It is possible for us to carry out drug discovery campaigns in various fields (gene therapy, oncology, etc.) using the Anchor system.

We can also offer to label a  protein target of your choice and watch the modulation of its expression by immunofluorescence in the presence of different inhibitors or activators of interest. Our screening platform equipment (CellInsight CX7) will allow us to perform many conditions in a short time and with sensitivity and quantification at the cellular level. We have a strong track record of screening campaign leading to drug discovery and patent protection.


Virus replication NeoVirtech

Our ANCHOR™ viruses are available in high-throughput imaging, making it a major tool for antiviral research and development. Combined with HCS microscopy and detection algorithm, it provides the fastest and the most robust techniques to discover new antivirals.

This allows us to rapidly set up the entire pre-clinical antiviral development pipeline:

  • drug discovery campaign (low, medium or high number of compounds), selectivity index calculation, hit sorting
  • hit validation and lead development
  • Determination of broad spectrum activities
  • Mechanism of Action
  • Target identification, resistant strain generation
Dr Daniel Gillet
We are developing inhibitors of intracellular trafficking pathways that block virus entry into cells. NeoVirTech’s technology allows for precise ranking of sets of analogues according to their antiviral potencies and selectivity indexes. Working with NeoVirTech was a great experience. Preparatory discussions were rich and efficient, adaptation of protocols to our needs was very successful, antiviral screening of our molecules was done rapidly, and activity reports were clear and informative. The team was always available to answer our questions. We warmly recommend NeoVirTech for the screening and potency assessment of antiviral molecules on designated viruses.
Dr Daniel Gillet
Frédéric Joliot Institute for Life Sciences, CEA Paris Saclay
Thursday, August 31, 2017
Enrique Tabares, CEO of MicroA A.S., Norway
Neovirtech have carried out several anti-viral studies for MicroA, on a range of targets. Both before and after the studies, we were impressed with their quick responses to our queries, very thorough technical approach and their support in data interpretation. Many thanks to the Neovirtech team for their hard work!
Enrique Tabares
CEO of MicroA A.S., Norway
Thursday, August 31, 2017